MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$24,952,378
Income tax benefit
(provision)
-$851,659
Pre-tax net loss
-$25,804,037
Change in fair value of
equity payable
-$201,862
Loss from operations
-$25,492,690
Interest expense
-$513,209
Total operating
expenses
$25,492,690
Impairment of in-process
research and development
$18,647,903
General and
administrative
$5,731,682
Research and development
$1,113,105
Back
Back
Income Statement
source: myfinsight.com
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)